ANAB · XBRL financial data

Anaptysbio financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ANAB's year ends in late June)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025	FY 2026Jun 30, 2026
Revenue from contracts with customers	63,175	10,287	17,157	91,280	234,603	—
Research and development	98,496	88,798	—	—	—	—
General and administrative	21,493	36,643	41,946	42,389	50,737	—
Total operating expenses	119,989	125,441	181,568	206,229	186,707	—
Operating income (loss)	(56,814)	(115,154)	(164,411)	(114,949)	47,896	—
Interest expense	0	—	—	—	—	—
Other income (expense)	37	12	(2)	14	5,430	—
Income tax expense (benefit)	0	24	(4)	3	164	—
Net income (loss)	(57,796)	(128,724)	(163,619)	(145,231)	(13,232)	—
Earnings per share, basic USD per share	(2.11)	(4.57)	(6.08)	(5.12)	(0.46)	—
Earnings per share, diluted USD per share	(2.11)	(4.57)	(6.08)	(5.12)	(0.46)	—
Weighted average shares, basic thousands of shares	27,431	28,165	26,924	28,382	28,758	—
Weighted average shares, diluted thousands of shares	27,431	28,165	26,924	28,382	28,758	—

Fiscal years (ANAB's year ends in late June)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025	FY 2026Jun 30, 2026
Cash and cash equivalents	495,729	71,308	35,965	123,080	238,196	133,826
Marketable securities	52,368	369,933	354,939	262,293	73,442	30,317
Marketable securities, non-current	67,097	142,935	27,026	35,470	0	0
Prepaid and other current assets	4,903	4,545	9,080	5,738	4,762	8,650
Total current assets	553,876	447,205	406,835	431,876	350,250	198,427
Property and equipment, net	2,283	2,089	2,098	1,849	1,370	102
Right-of-use asset	19,558	17,898	16,174	14,383	12,519	11,560
Total assets	643,070	610,383	452,389	483,834	364,395	316,984
Accounts payable	1,741	2,784	4,698	4,002	3,871	4,394
Accrued liabilities	12,853	21,633	30,967	39,501	32,674	28,798
Total current liabilities	16,099	26,054	37,442	45,428	38,625	35,353
Lease liability, non-current	19,450	17,813	16,037	14,112	12,032	10,934
Accumulated deficit	(321,753)	(450,477)	(614,096)	(759,327)	(772,559)	(641,563)
Total stockholders' equity	356,428	262,103	88,103	70,868	37,210	10,585
Total liabilities and equity	643,070	610,383	452,389	483,834	364,395	316,984
Common shares outstanding (cover page) thousands of shares	27,672	27,931	26,763	30,667	28,748	29,895

Fiscal years (ANAB's year ends in late June)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025	FY 2026Jun 30, 2026
Net income (loss)	(57,796)	(128,724)	(163,619)	(145,231)	(13,232)	—
Stock-based compensation	15,347	27,356	33,205	34,048	36,072	—
Depreciation and amortization	619	675	652	606	559	—
Net cash from operating activities	(45,920)	(73,593)	(120,800)	(135,337)	19,697	—
Purchases of property and equipment	1,366	358	807	358	87	—
Net cash from investing activities	38,835	(394,845)	144,754	95,398	228,032	—
Proceeds from issuing common stock	2,553	11,827	2,472	6,473	14,261	—
Share repurchases	0	0	50,000	456	68,626	—
Net cash from financing activities	252,298	44,017	(59,297)	127,054	(132,613)	—
Net change in cash	245,213	(424,421)	(35,343)	87,115	115,116	—

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Anaptysbio	133,826	27,488*	(26,640)*	29.9M	6.2 quarters	Q4 FY26 10-KTJun 30, 2026
Amphastar Pharmaceuticals	223,614	183,903	51,324*	42.5M	—	Q2 FY26 10-QJun 30, 2026
Stoke Therapeutics	107,271	11,255	(62,686)*	65.4M	5.2 quarters	Q3 FY26 10-QSep 30, 2026
Trevi Therapeutics	54,302	not reported	(17,429)*	142.5M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
ImmunityBio	75,670	51,240	(66,494)*	1.1B	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Anavex Life Sciences	118,326	not reported	(9,096)*	92.7M	13.0 quarters	Q3 FY26 10-QJun 30, 2026
Evolus	41,700	77,952	(1,933)*	66.2M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
Xencor	59,622	116,520	2,642*	75.0M	—	Q3 FY26 10-QSep 30, 2026
Immunome	217,706	0	(61,692)*	113.6M	8.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.